(Reuters) – Medical equipment maker Steris beat second-quarter profit estimates on Wednesday, on continued demand for non-urgent medical procedures that boosted sales of its surgical and examination tools.
The company has seen strong sales for the last few quarters due to sustained demand for healthcare services.
Steris continues to expect its fiscal 2025 revenue to increase in the range of 6.5% to 7.5%.
The Dublin-based company reiterated its adjusted profit forecast for fiscal 2025 of $9.05 per share to $9.25 per share. Analysts expect a profit of $9.16 apiece for the year.
The company posted quarterly revenue of $1.3 billion, in line with analysts’ estimates, according to data compiled by LSEG.
Revenue from the healthcare segment, under which Steris sells sterilization products to hospitals and other healthcare providers, grew 9% in the quarter to $944.2 million, ahead of estimates of $941.35 million.
Excluding items, the company reported adjusted profit of $2.14 per share, compared with analysts’ estimates of $2.12 per share.
(Reporting by Sruthi Narasimha Chari in Bengaluru; editing by Alan Barona)
Comments